Cargando…
A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
Programmed cell death protein-1 (PD-1)/programmed death protein ligand-1 (PD-L1) inhibitors for treatment of a various types of cancers have revolutionized cancer immunotherapy. However, PD-1/PD-L1 inhibitors are associated with a low response rate and are only effective on a small number of patient...
Autores principales: | Kong, Xianbin, Lu, Peng, Liu, Chuanxin, Guo, Yuzhu, Yang, Yuying, Peng, Yingying, Wang, Fangyuan, Bo, Zhichao, Dou, Xiaoxin, Shi, Haoyang, Meng, Jingyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985997/ https://www.ncbi.nlm.nih.gov/pubmed/33760188 http://dx.doi.org/10.3892/mmr.2021.12001 |
Ejemplares similares
-
Combination of UPLC–Q-TOF/MS and Network Pharmacology
to Reveal the Mechanism of Qizhen Decoction in the Treatment of Colon
Cancer
por: Kong, Xianbin, et al.
Publicado: (2021) -
Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
por: Cheng, Chao, et al.
Publicado: (2022) -
Is Weak Acid Beneficial for Addressing Checkpoint
Inhibitor–Triggered Cancer Hyper Progression in Anti-PD1/PD-L1
Immunotherapies?
por: Wan, Yulin, et al.
Publicado: (2020) -
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021) -
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)